Breaking News

Frontage Labs to Expand CMC Facility

June 3, 2014

To increase CMC workforce, capacity by more than 50%

Frontage Labs plans to expand its chemistry, manufacturing and controls (CMC) facility in Exton, PA, including significant capacity to existing services, as well as additional room for future growth.  
 
The initial phase renovation will include two analytical labs and 8000 sq.-ft. of office space, and is scheduled to be complete by the end of September.  The second phase includes additional clinical trial manufacturing (CTM) space for solid, semi-solid and sterile pharma products, packaging, labeling and distribution functions, and will be implemented at the beginning of 2015. Once the expansion is complete, the company expects to increase its CMC workforce and capacity by more than 50%. 
 
“We’re excited that consistent growth over recent years is enabling us to expand capacity and service offerings,” said Dongmei Wang, Senior Vice President of CMC Services. “The infrastructure improvements will allow us to meet ever-thriving client demand for product development support, while adding efficiency gains to small scale CTM production and laboratory throughput.”
 
Frontage’s CMC service portfolio includes organic synthesis, formulation development, GMP analytical testing and GMP clinical trial material manufacturing, for all types of drug candidates ranging from novel, early phase projects to generic-equivalent and consumer care medications. Over the last ten years, Frontage developed oral solid, semi-solid, liquid and sterile dosage forms that have been evaluated in clinical research programs and commercialized in the US, EU and Asian markets by its clients.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important